Patent · US Active

Progesterone receptor antagonists

US9085603B2 · kind B2 · utility

2Cited by

30References

15Claims

0Family size

Assignee

Bayer Intellectual Property GmbH · DE

Inventors

Wolfgang Schwede · Berlin, DE
Ulrich Klar · Berlin, DE
Carsten Möller · Berlin, DE
Andrea Rotgeri · Berlin, DE
Wilhelm Bone · Berlin, DE
Christoph Huwe · Berlin, DE

Key dates

Filing date	Feb 8, 2011
Grant date	Jul 21, 2015
Priority date	—
Expiry date	Nov 24, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/58
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of the formula I with a progesterone antagonizing effect and processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and also their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular of uterus fibroids (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeding, meningiomas, hormone-dependent breast cancers and troubles associated with the menopause or for monitoring fertility and emergency contraception.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.